(Q35676430)

9 August 2017

title

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients (English)

1 reference

9 August 2017

0 references

1 reference

1 reference

8

Mark J Ratain

1 reference

9 August 2017

7

Ezra E W Cohen

1 reference

9 August 2017

6

Federico Innocenti

1 reference

9 August 2017

Jacqueline Ramírez

1

1 reference

9 August 2017

Kehua Wu

2

1 reference

9 August 2017

Linda Janisch

3

1 reference

9 August 2017

Theodore Karrison

4

1 reference

9 August 2017

Larry K House

5

1 reference

9 August 2017

language of work or name

1 reference

23 August 2011

1 reference

Cancer Chemotherapy and Pharmacology

9 August 2017

published in

1 reference

9 August 2017

volume

68

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

1629-1632

1 reference

A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Irinotecan/thalidomide in metastatic colorectal cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

Influence of phenytoin on the disposition of irinotecan: a case report

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3259680

A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor

25 September 2018

1 reference

12 December 2020

Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

Effect of thalidomide on gastrointestinal toxic effects of irinotecan

1 reference

12 December 2020

Irinotecan and thalidomide in metastatic colorectal cancer

1 reference

12 December 2020

10.1007/S00280-011-1727-4

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference